Zobrazeno 1 - 10 of 79 pro vyhledávání: '"Dean A. Karalis"'
1
Akademický článek
Impact of the COVID-19 pandemic on the management of risk factors in patients with stable atherosclerotic vascular disease
Autor: Dean G. Karalis, Patrick Moeller, Albert Crawford, Maria Janelli, Scott E. Hessen
Publikováno v: American Journal of Preventive Cardiology, Vol 14, Iss , Pp 100499- (2023)
Background: Effective control of risk factors in patients with ASCVD is important to reduce recurrent cardiovascular events. However, many ASCVD patients do not have their risk factors controlled, and this may have worsened during the COVID-19 pandem
Externí odkaz: https://doaj.org/article/fe8f11d035524b678cc0fa377e5f3fb1
Zobrazit plný text záznamu
2
Nonadherence to lipid-lowering therapy and strategies to improve adherence in patients with atherosclerotic cardiovascular disease
Autor: Nihar R. Desai, Michael Farbaniec, Dean G. Karalis
Publikováno v: Clinical cardiologyREFERENCES.
Despite the availability of effective therapies that lower low-density lipoprotein cholesterol (LDL-C) levels in patients with atherosclerotic cardiovascular disease, many eligible patients are inadequately treated and their LDL-C levels remain subop
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d45e85bf5a3358c549996fb7f7bdb9f
https://pubmed.ncbi.nlm.nih.gov/36267039
Zobrazit plný text záznamu
3
Current and Emerging Therapies for Atherosclerotic Cardiovascular Disease Risk Reduction in Hypertriglyceridemia
Autor: Reed Mszar, Sarah Bart, Alexander Sakers, Daniel Soffer, Dean G. Karalis
Publikováno v: Journal of Clinical Medicine. 12:1382
Hypertriglyceridemia (HTG) is a prevalent medical condition in patients with cardiometabolic risk factors and is associated with an increased risk of atherosclerotic cardiovascular disease (ASCVD), if left undiagnosed and undertreated. Current guidel
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f174dc62b0c7ab2c240fb0891ff2a2e0
https://doi.org/10.3390/jcm12041382
Zobrazit plný text záznamu
4
Trends in PCSK9 Inhibitor Prescriptions before and after the Price Reduction in Patients with Atherosclerotic Cardiovascular Disease
Autor: Alexander Blake Smith, Joshua Banks, Scott W. Keith, Dean G. Karalis, Drew Johnson
Publikováno v: Journal of Clinical Medicine
Journal of Clinical Medicine, Vol 10, Iss 3828, p 3828 (2021)
Volume 10
Issue 17
Background: Proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors reduce low-density lipoprotein (LDL) cholesterol and cardiovascular event rates, yet due to their high price remain underutilized and difficult to prescribe in clinical prac
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91b61431a1251dd855a8847a1e7c0c8c
http://europepmc.org/articles/PMC8432238
Zobrazit plný text záznamu
5
Cascade Screening and Treatment Initiation in Young Adults with Heterozygous Familial Hypercholesterolemia
Autor: Dean G. Karalis, Nathan D. Wong, Robert C. Block, Matthew Bang, Amy L. Peterson
Publikováno v: Journal of clinical medicine, vol 10, iss 14
Journal of Clinical Medicine
Volume 10
Issue 14
Journal of Clinical Medicine, Vol 10, Iss 3090, p 3090 (2021)
Heterozygous familial hypercholesterolemia (HeFH) creates elevated low-density lipoprotein cholesterol (LDL-C), causing premature atherosclerotic cardiovascular disease (ASCVD). Guidelines recommend cascade screening relatives and starting statin the
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb3c5e1d143203fb925130a863819e53
https://escholarship.org/uc/item/10m9971s
Zobrazit plný text záznamu
8
Perceptions and Barriers on the Use of Proprotein Subtilisin/Kexin Type 9 Inhibitors in Heterozygous Familial Hypercholesterolemia (From a Survey of Primary Care Physicians and Cardiologists)
Autor: Nathan D. Wong, Dean G. Karalis, Amy L. Peterson, Matthew Bang, Robert C. Block
Publikováno v: The American Journal of Cardiology.
Heterozygous familial hypercholesterolemia (HeFH) results in significant elevations in LDL-C and premature atherosclerotic cardiovascular disease (ASCVD). Current guidelines recommend add-on proprotein subtilisin/kexin type 9 inhibitor (PCSK9i) thera
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9949b41db9b96132424d27c1290cd0a3
https://doi.org/10.1016/j.amjcard.2021.04.034
Zobrazit plný text záznamu
9
Awareness, diagnosis and treatment of heterozygous familial hypercholesterolemia (HeFH) - Results of a US national survey
Autor: Robert C. Block, Dean G. Karalis, Nathan D. Wong, Amy L. Peterson, Matthew Bang
Publikováno v: Journal of clinical lipidology. 15(5)
HeFH is a common inherited disorder that leads to markedly elevated LDL-cholesterol from birth and premature cardiovascular disease. HeFH is frequently underdiagnosed and undertreated.To compare how well primary care physicians and cardiologists reco
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37f5e17f7f8b9cfd2e5e493828cf4815
https://pubmed.ncbi.nlm.nih.gov/34593357
Zobrazit plný text záznamu
10
Managing cardiometabolic risk factors across a woman's lifespan: A lipidologist's perspective
Autor: Merle L. Myerson, Dianna Gaballa, Rodis Paparodis, Robert A. Wild, Eugenia Gianos, Maya Balakrishnan, Dean G. Karalis, Eliot A. Brinton, Guy Mintz
Publikováno v: Journal of clinical lipidology. 15(3)
A recent rise in atherosclerotic cardiovascular disease (ASCVD) mortality in women warrants a heightened focus on the cardiometabolic risk factors that are closely tied to increasing trends in obesity and suboptimal lifestyle. Polycystic ovarian synd
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::646d8c6b3b59f2a7602db8a69c3b5e99
https://pubmed.ncbi.nlm.nih.gov/33836983
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje